November 15 is World
Pancreatic Cancer Day
Novocure is proud to unite with people around the world to Demand Better in the fight against the world’s toughest cancer.
Learn More
dedicating decades
to cancer research
Professor Ignace Vergote conducts 20 ovarian cancer trials per year and has authored more than 800 papers in gynecologic cancers. He was an investigator in Novocure’s phase 2 pilot trial in recurrent ovarian cancer, INNOVATE.
Learn More
a skilled
communicator
Tomoe Kamata, Special Project Manager at Novocure Japan, uses her background in science and knack for interacting with people to market Novocure’s cancer therapy in Japan.
Learn More
‘it's like an
orchestra’
Ori Farber, Senior Medical Manager, shares what it’s like to work behind the scenes on Novocure’s company-sponsored clinical trials.
Learn More
‘they become
like family’
Matt Lozano, a Novocure Senior Device Support Specialist, shares the meaning he finds in working with patients and their caregivers.
Learn More
the story
of Novocure
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 495 employees and operations in the U.S., Europe and Asia.
Learn More
we can leverage physics to fight cancer
Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
OUR THERAPY
explore our clinical pipeline
Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to improving the lives of cancer patients
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD